<DOC>
	<DOCNO>NCT02638857</DOCNO>
	<brief_summary>Objectives : The purpose study evaluate safety efficacy dendritic cell-precision multiple antigen T cell transcatheter arterial chemoembolization treatment hepatocellular carcinoma . Methods： This study design novel therapy use dendritic cell-precision multiple antigen T cell . 60 patient enrol . They randomly divide transcatheter arterial chemoembolization group dendritic cell-precision multiple antigen T cell combine transcatheter arterial chemoembolization group . Treatments perform every 3 week total three period . The mail clinical indicator Progression-Free-Survival Overall Survival .</brief_summary>
	<brief_title>Immunotherapy Using Precision T Cells Specific Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization Treatment Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>A total 60 patient may enrol period 1-2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>1 . Age 18~65 year old , male female 2 . Signed informed consent 3 . Diagnosis hepatocellular carcinoma ( HCC ) , surgery perform TACE treatment carry . 4 . The recurrence HCC find operation without distant metastasis . 5 . The Eastern Cooperative Oncology Group ( ECOG ) score ≤2 6 . ChildPugh score liver function ≤ 9 7 . Routine blood meet requirement . 1 . Expected Overall survival ＜ 3 month 2 . The tumor size quantity suitable interventional treatment portal vein tumor thrombus 3 . Liver function Childs Pugh C 4 . Had receive TACE therapy previously radiotherapy present , take Sola Feeney 5 . Other serious disease : heart , lung , kidney , digestive , nervous , mental disorder , immune regulatory disease , metabolic disease , infectious disease , etc . 6 . Unable unwilling provide inform consent , fail comply test requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Recurrence Hepatocellular Carcinoma</keyword>
	<keyword>Advanced Hepatocellular Carcinoma</keyword>
	<keyword>Dendritic Cell -Precision Multiple Antigen T Cells</keyword>
	<keyword>Transcatheter Arterial Chemoembolization</keyword>
</DOC>